secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-04-05T23:59:59+00:00
Accession:  0001600620-23-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia reports positive renal biopsy data for LUPKYNIS in lupus nephritis
--------------------------------------------------------------------------

- Repeat biopsies from 16 voclosporin and 10 control patients over 18 months.
- Activity scores improved similarly in both arms; chronicity scores stable.
- Data differentiates LUPKYNIS from first-generation CNIs on nephrotoxicity.
- Further data to be presented at Congress of Clinical Rheumatology May 4-7, 2023.
- Conference call/webcast at 8:30 am EDT on April 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/0001600620-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000004/auph-20230405.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer